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Abstract
Background: In an ageing population, it is inevitable to improve the management of care for community-dwelling
elderly with incontinence. A previous study showed that implementation of the Optimum Continence Service
Specification (OCSS) for urinary incontinence in community-dwelling elderly with four or more chronic diseases
results in a reduction of urinary incontinence, an improved quality of life, and lower healthcare and lower societal
costs. The aim of this study was to explore future consequences of the OCSS strategy of various healthcare policy
scenarios in an ageing population.
Methods: We adapted a previously developed decision analytical model in which the OCSS new care strategy was
operationalised as the appointment of a continence nurse specialist located within the general practice in The
Netherlands. We used a societal perspective including healthcare costs (healthcare providers, treatment costs, insured
containment products, insured home care), and societal costs (informal caregiving, containment products paid
out-of-pocket, travelling expenses, home care paid out-of-pocket). All outcomes were computed over a
three-year time period using two different base years (2014 and 2030). Settings for future policy scenarios
were based on desk-research and expert opinion.
Results: Our results show that implementation of the OSCC new care strategy for urinary incontinence would
yield large health gains in community dwelling elderly (2030: 2592–2618 QALYs gained) and large cost-savings in The
Netherlands (2030: health care perspective: €32.4 Million - €72.5 Million; societal perspective: €182.0 Million - €250.6
Million). Savings can be generated in different categories which depends on healthcare policy. The uncertainty analyses
and extreme case scenarios showed the robustness of the results.
Conclusions: Implementation of the OCSS new care strategy for urinary incontinence results in an improvement in the
quality of life of community-dwelling elderly, a reduction of the costs for payers and affected elderly, and a reduction
in time invested by carers. Various realistic policy scenarios even forecast larger health gains and cost-savings in the
future. More importantly, the longer the implementation is postponed the larger the savings foregone. The future
organisation of healthcare affects the category in which the greatest savings will be generated.
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Background
Urinary incontinence is a common, but often neglected,
health condition that may impair the quality of life of af-
fected individuals. Reported prevalence rates range from 43
to 77% in nursing home residents [1] and from 4 to 55% in
elderly living in the community [2]. Urinary incontinence
is often considered as a condition inherent to ageing and
many affected individuals are unaware of available treat-
ments [2, 3]. As a consequence, it may take a long time
before people tend to seek medical advice; more than half
of the affected individuals never seek treatment [4, 5].
Urinary incontinence is often a taboo topic and affected
individuals experience feelings of stigma and emotional
and social distress [6]. Moreover, urinary incontinence is
associated with an increasing risk for falls, fall-related
injuries, skin problems, nursing home admissions, and
prolonged hospital admissions [7–9] and, consequently,
associated with high societal costs [9–11].
Several studies [12–14] have indicated areas for im-
provement in the management and treatment of urinary
incontinence, especially in elderly living in the community.
The Optimum Continence Service Specification (OCSS)
was developed in order to improve urinary incontinence
care in different healthcare settings for four different
incontinence patient profiles: i) stress and urgency urinary
incontinence, ii) faecal incontinence, iii) neurological
induced incontinence, and iv) urinary incontinence in the
elderly/ cognitively impaired [15]. The OCSS new care
strategy includes active case detection, initial assessment
and treatment, improved case coordination, caregiver and
community-based support, and use of containment
products and technologies [15].
A previous study showed that the implementation of
the OCSS new care strategy for urinary incontinence (by
the appointment of a nurse specialist in the General
Practitioner [GP] practice) in community-dwelling eld-
erly with four or more chronic diseases (i.e. the fourth
incontinence profile of the OCSS) resulted in a reduc-
tion of urinary incontinence, an improved quality of life,
and lower healthcare and lower societal costs in The
Netherlands [16]. This implies that postponing the im-
plementation of the OCSS new care strategy costs health
and money. Extrapolation of the results of Holtzer-Goor
et al. [16] suggest that if the new strategy would not be
implemented within the next 15 years, over €145 Million
and €585 Million of savings could be forgone in health
care and society, respectively. However, mainly due to
ageing of the population, it is expected that the number
of urinary incontinence affected individuals will rise in
the future [17]. Consequently, healthcare and societal
costs of continence care most likely further increase,
which implies that even greater potential savings could
be achievable. Moreover, there is an ongoing trend in
(Dutch) healthcare policymaking to shift formal care
(covered by insurance) to informal care and to lower the
degree of institutionalisation. These demographic and
policy changes, in combination with the impact of the
condition on the quality of life of patients and the role
of informal care givers, make it increasingly important
to improve urinary incontinence treatment pathways for
community-dwelling elderly. There is, however, no evi-
dence on the future costs and budgetary consequences
of continence care.
The objective of this study was to obtain insight into
future cost-effectiveness and budgetary consequences of
the implementation of the OCSS new care strategy for
the treatment of urinary incontinence in elderly with
four or more chronic diseases in the primary care setting
in The Netherlands and to explore the consequences of
various healthcare policy scenarios in an ageing
population.
Methods
We adapted our previously developed decision analytical
model [16] to calculate future cost-effectiveness and
budgetary consequences of the implementation of the
optimum continence service specification (OCSS) for
urinary incontinence in the primary care setting in The
Netherlands. In line with our previous assessment, we
computed all outcomes over a three-year time frame. In
this study, however, we used two different base years
(2014 and 2030) to enable a comparison of current and
future outcomes. Based on expert advice and predicted
trends published in the literature, we selected year 2030
as future base year. Further extrapolation would lower
the validity and reliability of the results.
Operationalisation of the optimum continence service
specification (OCSS)
The OCSS strategy is not yet implemented in The
Netherlands. Therefore, it was operationalised in our
model as the appointment of a nurse specialist (at a
master level) who is responsible for urinary continence
care within the GP practice in the Dutch primary care
setting. The implementation of this new care strategy
compared to usual care includes the following changes to
the current delivery of care: i) more active case detection;
ii) initial assessment and treatment by a continence nurse
specialist; and iii) improved case coordination [15]. The
appointed nurse specialist can either be specialised in con-
tinence care visiting several GP practices or specialised in
various chronic conditions (e.g., incontinence, stoma and
wound care) and appointed within one GP practice. The
type of nurse specialist proposed in this evaluation is re-
sponsible for urinary continence care and is specially
trained to carry out physical examinations, prescribe drugs
and containment products, and refer patients to specialist
care. Effectiveness estimates of care provided by the nurse
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specialist in terms of improvement of the condition (mean
21%) and successfully treated (mean 31%) were based on a
randomised controlled trial (RCT) by Subak et al. [18].
The international awareness study [19] provided input for
the estimations regarding the improvement of case-
detection, as this study indicated that the majority of in-
continence patients go undetected [16]. Given the lack of
evidence, no effects were assigned to improvements
related to case coordination.
Patient population
As in the previous model, the patient population con-
sists of community-dwelling elderly patients (≥65 years)
with four or more chronic diseases. The definition of
chronic disease was based on an existing list of the
International Classification of Primary Care (the ICPC-2
codes of O’Halloran [20] were recoded to ICPC-1 codes
used by the Dutch database). The target population was
estimated using data from two national databases
(Statistics Netherlands and the National Institute for
Health Services [NIVEL] Primary Care Database) in
combination with incidence and prevalence data from
the literature (Teunissen et al. [2] and Uijen et al. [21]).
Full details are published in Holtzer-Goor et al. [16].
Table 1 shows the key characteristics of the patient
population in the model.
Decision analytical model
The decision analytical model was developed to estimate
the incremental cost-effectiveness of the implementation
of the OCSS for urinary incontinence in The Netherlands
[16]. The model captures the complete pathway of Dutch
patients as identified by a series of interviews with health-
care experts (3 GPs, 3 pelvic physiotherapists, 2 continence
nurses, 3 gynaecologists, 2 surgeons, 2 urologists, a geriat-
ric specialist, a gastroenterologist, and a pharmacists [16]).
The pathway included a detection phase (detected and
never detected) and a treatment phase (treatment for cure
Table 1 Key characteristics of the patient population and overview of the settings of the current situation and the 2030 scenarios
Parameter Current situation
(2014)
Scenario 1
(2030)
Scenario 2
(2030)
Scenario 3
(2030)
Scenario 4
(2030)
Number of community-dwelling
elderly with ≥4 chronic diseasesa
860,741 1,420,369
(3.18% annual
increasee)
1,420,369 1,420,369 1,420,369
Total number of urinary
incontinence cases in population
(prevalent/ incident)
215,185/ 55,087 355,092/
90,904
355,092/90,904 355,092/90,904 355,092/90,904
% of the population annually
admitted to a nursing home
4% f 4% 4% 4% 2.95%
Number of patient-years ¥ 914,598 1,512,157 1,512,157 1,512,157 1,526,030
Formal home care (covered by
insurance)
(annual: 2% reduction of
users, and 1% increase of
# hours)
(annual: 2% reduction of
users, and 1% increase of
# hours)
(annual: 1% increase of #
of hours)
% users 47%b 47% 34.7% 34.7% 47%
# hours per week 6.4 hg 6.4 h 7.4 h 7.4 h 7.4 h
Reduction in home care in
improved/ success cases
10%/ 25% of
number of hours
(=0.64/ 1.6 h)c
0.64/ 1.6 h 0.64/ 1.6 h 0.64/ 1.6 h 0.64/ 1.6 h
Informal care (time of partner/
family/ friends)
(annual: 2% increase of
users and 1% increase of
# hours)
(annual: 2% increase of
users and 1% increase of
# hours)
% users 43%d 43% 57.9% 43% 57.9%
# hours per week 12 h d 12 h 13.9 h 12 h 13.9 h
Reduction in informal care in
improved/ success cases
10%/ 25% of
number of hours
(=1.2/ 3 h)c
1.2/ 3 h 1.2/ 3 h 0.8/ 2 h 0.8/ 2 h
Private home care (paid out-of-pocket by elderly)
% users n/a n/a n/a 15.6% 15.6%
# hours per week n/a n/a n/a 4.2 h 4.2 h
Reduction in private care in
improved/ success cases
n/a n/a n/a 0.4/ 1 h 0.4/ 1 h
Sources: a) The definition of chronic disease was based on ICPC-2 codes which were recoded to ICPC-1 codes [16]; b) Sorbye et al. [28]; c) Assumption; d) Langa et al.
[29]; e) Netherlands Institute for Social Research [22]; f) Holtzer-Goor et al. [16]; g) Eggink et al. [30]
¥ Total of number of patient-years in the three-year time period in the model (including an annual inflow and outflow [admittance to nursing home or mortality])
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plus containment, treatment for containment only, and
self-management). Patients who are never detected remain
in this category for the entire duration of the model.
Patients who are detected move to the assessment phase
and subsequently to the treatment phase. Only patients en-
tering the treatment for cure pathway move into a Markov
model consisting of three health states: i) incontinent; ii)
improvement; and iii) successfully treated. Full details of
the initial decision analytical model (including graphic
images of the model) have been published elsewhere [16].
Input parameters
Most of the model input parameters were identical to
the previous study. All were obtained from the literature
and national databases, or, in case no data was available,
based on expert opinion. Because no patient data was
used, ethical approval was not required. Full details are
published elsewhere [16]. This paragraphs only describes
the adaptations to the previous model. For the current
situation (base year 2014), we updated time-dependent
model input parameters (i.e., number of community-
dwelling elderly with four or more chronic diseases,
mortality data, and EURO 2014 prices). We used a two-
pronged approach for determining input parameters for
forecasting outcomes in 2030. First, a desk-research was
performed to retrieve information on trends in healthcare
policy and data on demographic developments in The
Netherlands, including predictions on ageing, mortality
and morbidity of the population. Second, we obtained ex-
pert opinion regarding future trends in healthcare policy.
In total, three experts participated in the expert panel: one
geriatric specialist, one expert from an insurance company
involved in healthcare procurement, and one professor in
healthcare policy and economics. The first expert meeting
focused on the discussion of recent and expected trends
in healthcare policy especially regarding the ageing popu-
lation and the Dutch healthcare system. Based on the first
meeting, scenarios were drafted by operationalising future
trends in policy. The experts provided written comments
on draft scenario settings. In the second expert meeting,
we discussed the adapted scenario settings and presented
preliminary results. After that, final adaptations were
made to the scenario settings. Finally, the experts provided
feedback on a draft version of the manuscript.
Scenarios for forecasting outcomes in 2030
To explore potential consequences of demographic changes
in combination with future policy trends, four different
scenarios were hypothesised. All scenario settings were
based on literature and expert opinion regarding future
policy trends. The first scenario only takes into account
demographic changes in age, mortality and morbidity of
the Dutch population (i.e. an annual increase of 3.18% of
the total number of community-dwelling elderly with four
or more chronic diseases [22]). The second scenario reflects
an ongoing shift from formal home care paid by the health
insurer to informal care provided by family and/or friends.
An annual reduction of 2% of the numbers of patients
using formal home care was assumed in combination with
an increase of 1% in the actual number of hours care
received (in 2030: 34.7% elderly receive on average 7.4 h
formal care per week). This is based on the assumption that
persons who no longer receive formal home care are the
ones with the lowest need for it. The shift to informal care
also results in an annual increase of 2% of informal care re-
ceivers alongside an increase of 1% of the number of hours
(in 2030: 57.9% of elderly receive on average 13.9 h infor-
mal care per week). The third scenario takes into account
the expectation that informal caregivers are not able to pro-
vide the extra amount of care needed. As a consequence,
elderly are forced buying private home care out-of-pocket
(unit price €27.80 per hour [23]; in 2030: 15.6% elderly buy
4.2 h per week private home care out-of-pocket). Finally,
the fourth scenario reflects a declining trend in institutiona-
lisation of the elderly (in 2030: 2.95%). In case more elderly
continue living in the community, they are most likely
more severely ill and need, therefore, more care (distributed
over formal home care, time investment from informal
caregivers, and private home care paid out-of-pocket). In
2030, 47% of elderly receive on average 7.4 h of formal
home care, 57.9% of elderly receive on average 13.9 h of
informal care, and 15.6% of elderly additionally buy on
average 4.2 h of private care out-of-pocket. Table 1 provides
an overview of the different scenario settings.
Statistical analyses and uncertainty analyses
The decision analytical model was developed in MS
Excel®; input parameters for the model were adapted for
each scenario (see Table 1). Outcomes were calculated
for a three-year time frame regarding incremental cost-
effectiveness at the patient level and budgetary impact at
the national level. Effectiveness estimates were reported
as percentage successfully treated and improved patients
as well as in Quality Adjusted Life Years (QALYs). The
QALY is the most common outcome measure in health
economic modelling [24]. One QALY stands for 1 year
in perfect health. In case an individual’s health is less
than perfect, QALYs are accrued at a lower rate (values
can range between 0 and 1). All outcomes were assessed
using a healthcare perspective (i.e. costs within the
healthcare setting covered within the basic benefit pack-
age) and a societal perspective (i.e. healthcare costs and
costs related to time investment due to informal care
giving, travelling expenses and other out-of-pocket
expenses). Parameter uncertainty was assessed as in the
initial model [16] using one-way sensitivity analysis
(OWSA) by varying each parameter within a range of
plus or minus 40% of the mean value. The results of the
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OWSA were presented in the form of a tornado diagram.
Probabilistic sensitivity analysis (PSA) was conducted to
assess the uncertainty of parameters simultaneously. Cost
parameters were then varied within a range of plus or
minus 20% of the mean value. For all parameter values
constrained between 0 and 1 (e.g. transition probabilities
and utilities), a Beta distribution was applied with a stand-
ard error equal to 20% of the mean. A Uniform distribu-
tion was assumed for the remaining input parameters.
Additional file 1: Table S1 provides details of all input
parameters which were included in the PSA, including the
base-case settings, probability distribution and their source.
Results
Clinical outcomes
Clinical outcomes were consistent in all scenarios
because no changes were made to the clinical input
parameters. Table 2 shows that the OCSS new care strat-
egy results in better patient outcomes in the incident
group as well as in the prevalent group. In the incident
group, the difference between usual care and the OCSS
new care strategy is 3.8 and 4.0% for successfully treated
and improved patients, respectively. In the prevalent
group, the difference is 3.4 and 3.1% for successfully
treated and improved patients, respectively.
Results at the individual patient level
Table 3 provides an overview of the results at the indi-
vidual patient level over a 3-year time period. The table
shows that the OCSS new care strategy results in a small
QALY gain (0.0051) and is less costly in comparison to
usual care in the current and all future scenarios. Total
savings per person per 3 year range between €59 [scenario
3] and €316 [scenario 4] in health care and between €355
[scenario 3] and €485 [scenario 4] in society.
There are only minor differences in costs at the individual
patient level between the current situation (2014) and
scenario 1 (2030) because the main difference in the model
is the total number of patient-years (i.e., differences due to
mortality rates are only observable in the decimals).
Scenario 2 shows, as expected, a shift from healthcare costs
to societal costs because of the shift from formal home care
paid by the insurer to informal care provided by family/
friends. Because we did not assume a 1:1 substitution ratio
(assumption that formal home care covered by the insurer
is more efficient), the increase in informal care costs
(difference between scenario 1 and 2: new care strategy
€6083 and usual care €6155) is higher compared to the
decline in costs in formal home care (difference between
scenario 1 and 2: new care strategy €3070 and usual care
€3106). Scenario 3 shows the results in case informal care
is partly replaced by privately out-of-pocket paid home
care. Similar, because we did not expect a 1:1 replacement
(assumption that people buy fewer hours privately out-of-
pocket compared to the number of hours provided by
family and/or friends), societal costs are lower compared to
scenario 2 (new care strategy: €14,381 vs. €17,518; usual
care: €14,677 vs. €17,896). As expected, scenario 4 predicts
the highest total costs at the individual patient level for
both care strategies (per 3 year: new care strategy €46,172
vs. usual care strategy €46,657). This scenario is the most
elaborated scenario regarding resource consumption.
However, because the new care strategy is less costly than
usual care in all scenarios, scenario 4 predicts the greatest
savings from both a healthcare and a societal perspective.
Budgetary consequences
Table 4 provides an overview of the budgetary
consequences. The implementation of the OCSS new
care strategy leads in all scenarios to lower costs than
usual care, irrespectively of using a healthcare or societal
perspective. The greatest savings are, however, incurred
by using a societal perspective. It should be noted that
the differences between the current situation (2014) and
scenario 1 (2030) are driven by the difference in the size
of the population due to demographic changes (i.e. total
number of patient-years over a 3-year time period).
Moreover, the size of the population also slightly in-
creases in scenario 4 (from 1.51 Million to 1.53 Million)
because fewer elderly are institutionalised and continue
living in the community in this scenario.
There are differences in which category the greatest costs
and cost-savings occur between the scenarios. Figure 1
shows the breakdown of the budgetary impact of the differ-
ent scenarios (Additional file 2: Table S2 provides full de-
tails). The implementation of the OCSS new care strategy
results in higher costs in three cost-categories within the
healthcare perspective: i) costs of the implementation of
the OCSS strategy, ii) treatment costs (including costs for
the GP, nurse specialist, physiotherapist, medical specialist,
and urinary incontinence related adverse events), and iii)
containment products paid by the insurer. The largest costs
are attributable to insured containment products. This is
mostly due to an increase in the detection-rate of patients
with incontinence. The other four cost-categories lead to
large savings; one category within the healthcare perspec-
tive (formal home care covered through insurance) and
three categories within the societal perspective (informal
Table 2 Clinical outcomes
Incident group Prevalent group
New
care
Usual
care
Difference New
care
Usual
care
Difference
% success 12.7% 9.0% 3.8% 3.4% 0.0% 3.4%
% improved 11.6% 7.7% 4.0% 3.1% 0.0% 3.1%
% not improved 75.6% 83.4% −7.7% 93.5% 100.0% −6.5%
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care provided by family/ friends, private home care paid
out-of-pocket, and other out-of-pocket expenditures).
The figure illustrates the great impact of different
healthcare policies. The shift from formal home care to in-
formal care in scenario 2 and 3 results in lower costs for
insured formal home care at the cost of a higher burden
for elderly and their family and friends (either in time
[scenario 2] or in time and money [scenario 3]). The
greatest savings are achieved in scenario 4 because it is
the most elaborate scenario on resource consumption. It
should be noted that the comparative results of scenario 4
need careful interpretation because of the fact that the
economic model only included costs related to urinary in-
continence in community-dwelling elderly. Expenditures
and/or savings in urinary incontinence affected elderly in
other healthcare settings (e.g. elderly living in a nursing
home) were not taken into account.
Uncertainty analyses
The impact of each input parameter of the model on the
incremental costs (per person) was assessed using
one-way sensitivity analysis. The tornado diagram (see
Fig. 2) shows the ten most influential parameters in sce-
nario 1 (2030). This scenario presents an extrapolation
to 2030 of the current situation (2014). In that sense, it
represents the base case scenario for future predictions.
The ranges of incremental costs are always negative,
thus result in lower costs except when the percentage of
incidence cases treated for containment only in the new
care strategy is increased from 61 to 85%. In this case,
the new care strategy could be slightly more costly
(€7.87 per patient in 3 years). We observed that parame-
ters associated with the effectiveness of the new care
strategy are the most influential on the incremental
costs. In particular, we observed that increasing the per-
centage of incidence cases treated for containment only,
the detection rate of urinary incontinence by the nurse
specialist, or the success rate of the new care strategy re-
sulted in decreasing costs. Other influential parameters
on the incremental costs are associated with the costs of
formal home care (unit costs per hour, number of hours
provided per week, and reduction of hours in success
cases), the frequency of use of formal and informal care
in patients treated with usual care, and the out-of-
Table 4 Budgetary impact of implementing the OCSS new care strategy over a period of 3 years
Current situation (2014) Scenario 1 (2030) Scenario 2 (2030) Scenario 3 (2030) Scenario 4 (2030)
Total number of patient-years a 914,598 1,512,157 1,512,157 1,512,157 1,526,030
Healthcare perspective -€ 30.709 M -€ 50.816 M -€ 32.410 M -€ 32.410 M -€ 72.481 M
Societal perspective -€ 124.659 M -€ 206.160 M -€ 224.231 M -€ 182.031 M -€ 250.637 M
M million
a Total of number of patient-years in the three-year time period (including an annual inflow and outflow)
Fig. 1 Breakdown of the 3-year budgetary impact
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pocket expenditures for containment products incurred
by patients managing urinary incontinence with
self-care.
The tornado diagrams (not shown) from the other
scenarios are similar to scenario 1 (Fig. 2). In fact, the
same 10 parameters are most important, but from rank
7 onwards some of the parameters change position.
The results of the propobabilistic sensitivity analysis
(PSA; all parameters varied at the same time) are similar for
all scenarios. The new care strategy is, on average per per-
son, more effective and less costly compared to usual care.
The gain in QALYs ranges from 0.0045 (current situation
and scenario 2) to 0.0048 (scenario 1). The incremental cost
savings range from €315 (scenario 3) to €430 (scenario 4).
Table 5 also shows the PSA estimates for the probability
that the new care strategy is i) more effective, ii) less costly,
iii) dominant (i.e., more effective and less costly), and iv)
cost-effective at a threshold of €20,000. The least favorable
setting for the new care strategy is the one considered in
scenario 2 (estimated probabilities: 93.0, 92.3, 91.4, and
92.4%, respectively). Table 5 shows a summary of the PSA
results.
Furthermore, the implementation of the OCSS new care
strategy remained cost-saving even in extreme case sce-
narios. For example, halving the reduction in numbers of
hours formal home care and informal care in success
(reduction from 25 to 12.5%) and improved (from 10 to
5%) patients resulted in almost halving the cost-savings in
both categories (budgetary impact formal home care: from
€129 Million to €65 Million; informal care: from €65
Million to €33 Million), and almost halving (from €206
Million to €109 Million) the total societal savings (using
the settings in scenario 1). Although the implementation
of the OCSS new care strategy remained less costly at the
individual patient level using a societal perspective (€211
lower costs per patient per 3 year), total costs increased,
however, in case of using a healthcare perspective (from
€96 lower costs to €31 per patient per 3 year). Another
Fig. 2 Tornado diagram showing the impact of the ten most influential parameters on the incremental costs for scenario 1
Table 5 Summary of the PSA results
Model outcome Current situation
(2014)
Scenario 1
(2030)
Scenario 2
(2030)
Scenario 3
(2030)
Scenario 4
(2030)
Incremental QALYs per person
(2.5%;97.5% percentiles)
0.0045
(−0.0010;0.0130)
0.0048
(−0.0007;0.0144)
0.0045
(−0.0015;0.0136)
0.0046
(−0.0009;0.0137)
0.0047
(− 0.0009;0.0135)
Incremental costs per person
(2.5%;97.5% percentiles)
-€345
(−€989; €76)
-€364
(−€994; €42)
-€373
(−€993; €116)
-€315
(−€893; €61)
-€430
(−€1150; €68)
Probability new care is more effective 93.6% 95.0% 93.0% 93.9% 93.8%
Probability new care is less costly 93.7% 94.8% 92.3% 94.0% 94.6%
Probability new care is dominanta 92.7% 93.7% 91.4% 92.8% 93.1%
Probability new care is cost-effective
at €20,000/ QALY threshold
93.8% 95.0% 92.4% 94.4% 94.4%
QALY quality adjusted life years
a Dominant means that the new care is more effective and cost-saving
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extreme case scenario showed the impact of assigning the
reduction in the numbers of hours in success and
improved patients to either informal care or private care
paid out-of-pocket (using the settings in scenario 3). The
former scenario resulted in even greater total cost-savings
(i.e. the additional savings in informal care [€22 Million]
outweigh the additional costs in home care paid out-of-
pocket [€16 Million]). Although savings (€32 Million) in
private care paid out-of-pocket tripled in the latter sce-
nario (from €16 Million to €48 Million), this did not out-
weigh the additional costs in informal care (€44 Million).
Discussion
We investigated the long-term impact of implementing the
OCSS new care strategy for urinary incontinence for
community-dwelling elderly with four or more chronic dis-
eases in The Netherlands. A previous study showed that
the appointment of a nurse specialist (who improves case
detection, treatment effectiveness, and case-coordination)
would result in a reduction of urinary incontinence, and
thereby would lead to an improved quality of life, lower
healthcare, and lower societal costs in community-dwelling
multi-morbid elderly in The Netherlands [16]. Because of
demographic changes in an ageing population, the number
of elderly affected with urinary incontinence will rise in the
future [17]. Our future scenarios (in 2030) reveal that these
changes only further necessity an appropriate strategy to
manage the increasing needs of elderly living in the com-
munity. Although we cannot foretell future healthcare pol-
icies, our results illustrate that various realistic policy
scenarios (defined by experts) lead to large health gains
and cost-savings by implementing the OSCC new care
strategy for urinary incontinence in 2030 (QALYs:
2592–2618; costs health care perspective: €32.4 -€72.5
Million; costs societal perspective: €182.0–250.6 Million).
The different scenarios clearly explicate where the greatest
cost-savings can be generated (i.e., healthcare payer,
society, or the affected elderly and his/her family). We
estimated that there is a high probability (> 92% in all our
scenarios) that the OCSS new care strategy is more effect-
ive and less costly, irrespectively of healthcare setting. Even
in extreme case scenarios our results appeared to be rather
robust and the implementation of the OCSS new care
strategy remained cost-saving compared to usual care.
Several studies [12–14] indicated areas for improvement
in the management and treatment of urinary incontin-
ence. Our results show that improvement of care path-
ways by implementing a continence nurse specialist not
only results in better clinical outcomes but also contrib-
utes to important cost-savings. It should be noted that our
study only investigated consequences in the community
setting. Therefore, some of the savings and/or expendi-
tures in care for community-dwelling elderly with urinary
incontinence may be at the cost of spending and/or saving
money in urinary incontinence affected elderly in non-
community settings. For example, the population in the
fourth scenario is slightly different from the first three
scenarios (i.e., greater number of patient life-years over a
3-year time period due to a lower rate of institutionalisa-
tion [1,526,030 vs. 1,512,157]). Therefore, the results on
the budgetary impact between the scenarios need careful
interpretation.
The effectiveness estimates of care provided by a nurse
specialist in our study are based on an RCT by Subak et al.
[18] and on the awareness study [19]. Other studies re-
ported conflicting outcomes regarding the effectiveness
and costs of a nurse specialist. These studies are, however,
not entirely comparable to our study. Moore et al. [25] re-
ported no differences in health outcomes between conser-
vative treatment provided by continence nurse advisors
and urogynaecologists in the United Kingdom (UK). A
more recent study in the UK by Williams et al. [26] showed
better health outcomes due to the new nurse led service
but at higher costs. In contrast to our study, Williams et al.
[26] did, however, not include costs of formal home care
and informal care. Although in our study costs related to
other healthcare resources also rise, savings related to for-
mal home care are much greater. Similarly, a Dutch study
by Albers-Heitner et al. [27] did not include costs of formal
home care and informal care. This, in combination with
the fact that they only used a one-year timeframe (which
resulted in higher implementation costs), mainly explains
the differences in results. Furthermore, previous results of
the model published by Holtzer-Goor et al. [16] showed
that the new care strategy still yielded QALY gains and re-
sulted in lower costs even in case the new care strategy
was assumed only to impact the detection rate and not the
effectiveness rate. Our extreme case scenarios further
underline the robustness of our results.
To our knowledge, no other studies investigated future
consequences of the introduction of a nurse specialist led
service. The expected increase in numbers of community-
dwelling elderly with urinary incontinence in combination
with the impact of the condition makes it increasingly im-
portant to improve urinary incontinence care pathways.
Our results are specific for The Netherlands where the GP
has an important role in the treatment and coordination
of care for community-dwelling elderly with urinary incon-
tinence (the GP acts as a gatekeeper to specialist care).
Other countries may have a different organisation of the
healthcare system and the primary care setting. Moreover,
(future) healthcare policies are context specific. Although
beyond the scope of our study, in case the new care strat-
egy will be implemented, the description and details of this
nurse led service and its finance mechanism should be fur-
ther developed based on the components as described by
Wagg et al. [15] taking into account context specific
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healthcare policies and organisation. We believe, however,
that our study provides valuable insights for (primary)
healthcare settings in other countries.
Our extensive analyses including several realistic policy
scenarios illustrate that investing in the improvement of
urinary incontinence treatment pathways most likely re-
sults in large health gains and large cost-savings, irrespec-
tively of the healthcare setting. Although the average
impact at the individual patient level seems relatively small
(i.e. QALY gain: 0.005; cost-savings: €59 - €316 in health-
care and €355 - €485 in society), it is important to realise
that many patients remain undetected or receive care for
containment only in which case no gains were assigned in
the model. Thus, the impact in individual patients who
were successfully treated is much greater.
To maintain sustainability of the healthcare system, there
is an ongoing trend to lower the degree of care covered
within the basic benefit package (including lowering the
rate of institutionalisation) and to emphasise the expanding
role of informal care. This may result in an increase of un-
met needs and may put pressure on informal caregivers
and/or on personal budgets. The extent to which the con-
sequences put pressure on the elderly and their family may
differ by country. However, we believe that other countries
experience similar issues as The Netherlands, albeit to a
varying degree.
Because future consequences of demographic and
healthcare policy changes are not yet clear, it is crucial
to carefully evaluate their potential impact and facilitate
the increasing needs appropriately. The OCSS strategy is
an example how a new care strategy can be implemented
to facilitate such changes and, simultaneously, improve
the sustainability of the system, irrespectively of the
healthcare setting. More importantly, our study reveals
that implementation of the OSCC new care strategy is
cost-saving from a healthcare as well as from a societal
perspective, irrespective of whether it is implemented
now or in the future. However, our results also clearly
highlight the great urgency to implement such a strategy
in the near future. Postponing the implementation
implies foregoing large health gains and savings. For
example, assuming linearity (i.e., average of the current
scenario [2014] and scenario 1 [2030]) would imply
foregoing €204 Million savings in health care and
€827 Million savings in society in the next 15 years
in The Netherlands. Similarly, community-dwelling
elderly can gain on average 693 QALYs per year.
Thus, this would imply forgoing 10,401 QALYs in the
next 15 years. Furthermore, informal care was computed
as costs for society, which is best practice in economic
evaluations. Informal caregiving is, nevertheless, time
spend on caregiving instead of time spend on, for ex-
ample, work or leisure. Implementation of the OSCC new
care strategy would result in 1.27 Million fewer hours of
informal caregiving per year (19.09 Million hours in the
next 15 years).
Finally, it should be mentioned that there is limited
data available for various areas of incontinence care [16].
In The Netherlands, the role of the nurse specialist is
quite new and it will take some time before a program
like the OCSS can be delivered on a large scale. It is,
therefore, of utmost importance to introduce the OCSS
in a study setting and carefully monitor all aspects.
Conclusion
Prevalence and incidence of urinary incontinence will rise
in an ageing population which will put pressure on current
treatment pathways. It is, therefore, inevitable to improve
the management of care for community-dwelling elderly
with incontinence. Implementation of the OCSS for urin-
ary incontinence most likely results in a reduction of urin-
ary incontinence, an improvement in the quality of life in
community-dwelling elderly, a reduction of the costs for
payers and affected elderly, and a reduction in time
invested by carers. Although we cannot foretell the future,
our study indicates that various realistic policy scenarios
forecast even larger savings in the future. More import-
antly, the longer the implementation of such a program is
postponed the larger the health gains and cost-savings
foregone. The future organisation of healthcare influences
where the greatest savings can be generated.
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